Laboratoires Pierre Fabre and XtalPi announce AI-driven collaboration focused on drug discovery
November 9, 2026 | Monday | News
To accelerate the identification of high-quality clinical candidates across multiple research programmes in oncology
image credit- freepik
France-based Laboratoires Pierre Fabre and China's XtalPi have announced an agreement under which they will collaborate on the discovery of novel clinical candidates across a number of research programmes in the field of oncology, potentially dermatology, and rare diseases.
Under the agreement, XtalPi will use its integrated AI capabilities and robotics platform to de novo design and deliver novel small molecule therapeutics against undisclosed targets. Laboratoires Pierre Fabre will contribute with its expertise in disease biology, discovery, translational research, and clinical development to select and advance the most promising compounds, and will be responsible for subsequent clinical and commercial development.
The collaboration reflects the parties' shared interest in exploring challenging and historically hard-to-drug targets—an area associated with significant unmet medical need and substantial opportunity in innovative drug discovery.
For Laboratoires Pierre Fabre, this agreement represents a strategic addition to its R&D roadmap, strengthening its drug discovery capabilities. It also advances XtalPi's efforts to apply AI and robotics to de novo drug discovery. Together, the companies aim to accelerate the identification of high-quality clinical candidates across multiple research programmes in oncology and potentially other therapeutic areas.
